The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. To date, nearly 15,000 people have participated in casirivimab and imdevimab clinical trials. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Production 52

The Pharma Data

JANUARY 27, 2021

The report entitled “Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women” was written by nurse practitioner Melissa Fesler and internist Raphael Stricker from the Alan E. The fact that HCQ treatment became politicized added to the controversy over its value for COVID-19 therapy. The study is available at [link].

Vaccine 52

Vaccine Nurses International Treatment 52

Drug Target Review

AUGUST 16, 2024

Advances in gene editing, personalised medicine, and regenerative therapies are improving patient outcomes and changing the landscape of healthcare. In those roles, she oversaw the direction, planning, execution and interpretation of clinical trial data.

Medical Schools 106

Medical Schools Nurses Research Production 106

The Pharma Data

NOVEMBER 19, 2020

A study out of Rutgers University found that healthcare staffers, especially nurses, have a higher prevalence of COVID-19 than non-healthcare workers. The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. Healthcare Workers Most at Risk for COVID-19.

Research 52

Research Nurses Disease Immune Response 52

Olympian Clinical Research

JUNE 25, 2020

Environmental changes such as travel, hospitalization, new visitors, etc. Changes in living situation, such as moving to a new residence home or nursing home. Make time for soothing activities such as massage therapy, calming music, and reading. The introduction of a new caregiver. Misperceived threats. Fear and fatigue.

Nurses 78

Nurses Clinical Research Clinical Trials Hospitals 78

The Pharma Data

DECEMBER 3, 2020

The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., About Maribavir.

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

On Medicine

FEBRUARY 26, 2023

After many trials, and misdirection to the sexual health clinic, at the age of twenty-three, Daniella was finally diagnosed with Behçet’s disease. In addition to meaningful specialized treatment, Daniella uses her creative pursuits as a form of therapy, inspiring others living with chronic health issues through the use of her podcast.

Disease 40

Disease Nurses Treatment Doctors 40

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. INDIANAPOLIS, Jan. have reached record highs.

Hospitals 52

Hospitals Treatment Long-Term Care Facilities Trials 52

The Pharma Data

JUNE 18, 2021

“The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment,” said Mohamed Zaki , M.D., NORTH CHICAGO, Ill. NORTH CHICAGO, Ill. with Ven-Obi versus 83.1%

Treatment 40

Treatment Trials Therapies Clinical Trials 40

The Pharma Data

NOVEMBER 20, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19 , has received Emergency Use Authorization (EUA) from the U.S. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . TAMPA, Fla., For more information, visit health.usf.edu.

Hospitals 40

Hospitals Treatment Virus Nurses 40

The Pharma Data

NOVEMBER 21, 2020

NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA).

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

AUGUST 11, 2020

.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

Eli Lilly expanded its ongoing BLAZE-4 study to include Vir’s monoclonal antibody in the trial. Data published last week showed that bamlanivimab significantly reduced COVID-19 risk for nursing home residents in a Phase III trial. . Food and Drug Administration to treat mild-to-moderate COVID-19 patients.

Virus 52

Virus Nurses Research Laboratories Trials 52

The Pharma Data

APRIL 28, 2021

The positive CHMP opinion is a scientific recommendation for marketing authorization to the European Commission (EC), which is expected to deliver its final decision on VENCLYXTO combination therapy for use in AML in the first half of 2021. The positive CHMP opinion represents the third for an extension of indications for VENCLYXTO.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

DECEMBER 1, 2020

13 to 17 and attracted participants from around the world, including cardiovascular specialists, surgeons, and nurses as well as other health care professionals. “It is important to remember that this is a single clinical trial,” Maruthur said. AHA: Obese Patients More Likely to Be Hospitalized for COVID-19.

Hospitals 52

Hospitals Disease Treatment Nurses 52

The Pharma Data

AUGUST 11, 2020

The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. PRINCETON, N.J.–(

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. Clinical Trials. December 6, 2020 12:00 PM – 1:30 PM; Track: 7. Antiepileptic Drugs / 7B.

Protein Expression 52

Protein Expression Clinical Trials Pharmacokinetics Trials 52

The Pharma Data

JUNE 18, 2021

“Combining our novel therapies to deliver a new potential treatment is an example of AbbVie’s innovative approach to identify options for difficult-to-treat blood cancers, like CLL,” said Mohamed Zaki , M.D., IMBRUVICA has been granted four Breakthrough Therapy Designations from the U.S.

Treatment 40

Treatment FDA FDA Approval Therapies 40

The Pharma Data

JUNE 18, 2021

Time to subsequent therapy was longer for I+V (HR 0.143, 95% CI 0.05-0.41). “We are encouraged by these results, which further support the efficacy of these two well-established therapies,” said Mohamed Zaki, M.D., IMBRUVICA has been granted four Breakthrough Therapy Designations from the U.S. About the GLOW Study.

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

JULY 23, 2021

. “Serious infections in children can be difficult to treat and the impact of ABSSSI among children is significant, as these infections often require IV antibiotics, resulting in hospitalization,” said Margaret Burroughs, medical director, infectious diseases, AbbVie.

FDA Approval 52

FDA Approval FDA Clinical Trials Trials 52

The Pharma Data

MAY 13, 2021

And I was rushed to hospital in the back of an ambulance… As paramedics desperately tried to keep me alive. I could hear doctors and nurses speaking in hushed tones…. And Mary-Anne, a nurse from Arkansas, who says…. I’d always assumed that Jen just did estrogen replacement therapy or something like that…. Jenn told me.

Production 52

Production Packaging Doctors Research 52

The Pharma Data

MAY 13, 2021

Spend a few years in trial and error testing. A study published in World Journal of Gastrointestinal Pharmacology[3] revealed Pancreatic enzyme replacement therapy has been shown to treat pain caused in chronic pancreatitis. That took a lot of time to test and figure out. That said: You can do this on your own if you want.

Doctors 52

Doctors Production Research Science 52